Wheat allergy immunotherapy - DBV Technologies

Drug Profile

Wheat allergy immunotherapy - DBV Technologies

Alternative Names: Wheat Oral Immunotherapy; Wheat-OIT

Latest Information Update: 30 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator DBV Technologies
  • Class Food allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Food hypersensitivity

Most Recent Events

  • 13 Apr 2017 DBV Technologies completes a phase I/II trial in Food allergy (In children, In adolescents, In adults) in USA (PO) (NCT01980992)
  • 03 Mar 2017 Efficacy and adverse events data from a clinical trial in Food allergy presented at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top